Skills (1)
Publications (26) View all
-
Article: Long-Term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of HBV-Related Cirrhosis.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND & AIMS: Data are limited on the efficacy and safety of tenofovir and entecavir when given for more than 1 year to patients with hepatitis B-related cirrhosis. We investigated the long-term safety and efficacy of these antiviral drugs in patients with chronic hepatitis B virus (HBV) infection, with compensated or decompensated cirrhosis, and compare results with those from lamivudine. METHODS: We performed a retrospective analysis of data from 227 adult patients with chronic HBV infection who were diagnosed with cirrhosis, beginning in 2005, at 18 centers throughout Turkey; 104 had decompensated cirrhosis, 197 were treatment naïve before 72 received tenofovir (followed for 21.4±9.7 months), 77 received entecavir (followed for 24.0±13.3 months), and 74 received lamivudine (followed for 36.5±24.1 months). We collected data on patient demographics and baseline characteristics. Laboratory test results, clinical outcomes, and drug-related adverse events were compared among groups. RESULTS: Levels of HBV DNA <400 copies/mL were achieved in 91.5%, 92.5%, and 77% of patients receiving tenofovir, entecavir, or lamivudine, respectively. Levels of alanine aminotransferase normalized in 86.8%, 92.1%, and 71.8% of patients that received tenofovir, entecavir, and lamivudine, respectively. Child-Turcotte-Pugh scores increased among 8.5% of patients that received tenofovir, 15.6% that received entecavir, and 27.4% that received lamivudine. Frequencies of complications from cirrhosis, including hepatic encephalopathy, variceal bleeding, hepatocellular carcinoma, and mortality were similar among groups. Lamivudine had to be changed to another drug for 32.4% of the patients. CONCLUSION: Tenofovir and entecavir are effective and safe for long-term use in patients with compensated or decompensated cirrhosis from HBV infection.Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 10/2012; · 5.64 Impact Factor -
Article: Does mean platelet volume influence the attack or attack-free period in the patients with Familial Mediterranean fever?
[show abstract] [hide abstract]
ABSTRACT: Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease which is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas-like skin disease. Mean platelet volume (MPV) is a sign of platelet activation. There are limited studies in the literature about MPV levels in FMF patients. We aimed to investigate MPV levels during the attack period (group 1) and attack-free periods (group 2) in FMF patients, and to compare them with healthy controls (group 3). The study consisted of the data of: 60 group 1 patients, 120 group 2 patients, and 75 group 3 patients. Erythrocyte sedimentation rate, C-reactive protein, white blood cell count, platelet count, and MPV levels were retrospectively recorded from patient files. Statistical analyses showed that MPV was significantly lower in FMF patients both in group 1 and group 2 than in group 3 (p = 0.004, p = 0.002, respectively); however, there was no difference among group 1 and group 2 in patients with FMF (p = 0.279). The mean platelet count of group 1 was higher than that of group 3 (p = 0.010). In conclusion, this study results suggested that MPV level did not increase on the contrary, it decreased in patients with FMF both in group 1 and/or group 2 when compared to group 3. It was concluded that the lower MPV level was an expected result of secondary thrombocytosis in FMF patients.Platelets 06/2012; · 1.85 Impact Factor -
Article: A rare cause of bleeding esophageal varices: Alström syndrome.
Gastroentérologie Clinique et Biologique 04/2012; · 0.80 Impact Factor -
Article: Iatrogenic pneumoscrotum after colonoscopy.
The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 08/2011; 22(4):443-4. · 0.47 Impact Factor -
Article: Endoscopic removal of an iatrogenically induced rectal foreign body.
The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology 04/2011; 22(2):228-9. · 0.47 Impact Factor
